SORAFENIB

Targeted Cancer Therapy

Brand names: sorafenib

Oral

Targeted Cancer Therapy agent

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic

progressive

differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

5) Risk of Impaired Wound Healing: Withhold sorafenib tablets for at least 10 days prior to elective surgery
7) QT Prolongation: Monitor electrocardiograms and electrolytes in patients at increased risk for ventricular arrhythmias
Advise patients of the potential risk to a fetus and to use effective contraception
2 Hemorrhage An increased risk of bleeding may occur following sorafenib tablets administration

11 documented side effects by frequency

Diarrhea

>10%

Fatigue

1-10%

Rash

1-10%

Decreased Appetite

1-10%

Nausea

1-10%

Weakness

1-10%

High Blood Pressure

1-10%

Fever

0.1-1%

Vomiting

0.1-1%

Limb Pain

0.1-1%

Weight Loss

0.1-1%

No community discussions found for SORAFENIB yet.

15 available comparisons

Dosage Forms

Tablet

Route

Oral